NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
Clinical Trials
16 trialsNCT01826864 2020-07-27
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Jonsson Comprehensive Cancer Center
Phase 3 Withdrawn
NCT01322490 2019-09-04
Prospect
Bavarian Nordic
Phase 3 Completed
NCT01875653 2019-05-10
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Lisata Therapeutics, Inc.
Phase 3 Terminated
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01479244 2017-02-27
PRESENT
Galena Biopharma, Inc.
Phase 3 Completed
NCT00769704 2016-07-13
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
BioVex Limited
Phase 3 Completed
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01368276 2015-12-18
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
BioVex Limited
Phase 3 Completed
NCT00003093 2014-08-01
Combination Chemotherapy in Treating Children With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00003958 2013-06-17
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Completed
NCT00091676 2012-02-03
BiovaxID
Biovest International
Phase 3 Unknown
NCT00880243 2009-04-13
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
Acute Leukemia French Association
Phase 3 Completed
NCT00001338 2008-03-04
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00001561 2007-09-24
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
National Institutes of Health Clinical Center (CC)
Phase 3 Completed